Petros Pharmaceuticals, Inc. Cost of Revenue
Petros Pharmaceuticals, Inc. (PTPI) reported Cost of Revenue of $1.21 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2025-03-31
- Petros Pharmaceuticals, Inc. cost of goods and services sold for the quarter ending 2024-12-31 was $264.75K, a 67.41% increase year-over-year.
- Petros Pharmaceuticals, Inc. cost of goods and services sold for the quarter ending 2024-09-30 was $287.00K, a 29.74% decline year-over-year.
- Petros Pharmaceuticals, Inc. cost of goods and services sold for the quarter ending 2024-06-30 was $329.11K, a 35.95% decline year-over-year.
- Petros Pharmaceuticals, Inc. cost of goods and services sold for the quarter ending 2024-03-31 was $331.83K, a 39.75% decline year-over-year.
- Petros Pharmaceuticals, Inc. cost of goods and services sold for fiscal 2024 was $1.21M, a 25.66% decline from fiscal 2023.
- Petros Pharmaceuticals, Inc. cost of goods and services sold for fiscal 2023 was $1.63M, a 28.75% decline from fiscal 2022.
- Petros Pharmaceuticals, Inc. cost of goods and services sold for fiscal 2022 was $2.29M, a 43.13% increase from fiscal 2021.
- Petros Pharmaceuticals, Inc. cost of goods and services sold for fiscal 2021 was $1.60M, a 60.47% decline from fiscal 2020.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2024-12-31 | $264.75K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $551.76K derived: sum of 2 quarters · filed 2025-03-31 | $880.87K derived: sum of 3 quarters · filed 2025-03-31 | $1.21M 10-K · filed 2025-03-31 |
| 2024-09-30 | $287.00K 10-Q · filed 2024-11-13 | $616.12K derived: sum of 2 quarters · filed 2024-11-13 | $947.95K 10-Q · filed 2024-11-13 | $1.11M derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-06-30 | $329.11K 10-Q · filed 2024-08-14 | $660.94K 10-Q · filed 2024-08-14 | $819.09K derived: sum of 3 quarters · filed 2025-03-31 | $1.23M derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-03-31 | $331.83K 10-Q · filed 2024-05-15 | $489.98K derived: sum of 2 quarters · filed 2025-03-31 | $898.45K derived: sum of 3 quarters · filed 2025-03-31 | $1.41M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | $158.15K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $566.62K derived: sum of 2 quarters · filed 2025-03-31 | $1.08M derived: sum of 3 quarters · filed 2025-03-31 | $1.63M 10-K · filed 2025-03-31 |
| 2023-09-30 | $408.48K 10-Q · filed 2024-11-13 | $922.33K derived: sum of 2 quarters · filed 2024-11-13 | $1.47M 10-Q · filed 2024-11-13 | $2.35M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $513.86K 10-Q · filed 2024-08-14 | $1.06M 10-Q · filed 2024-08-14 | $1.95M derived: sum of 3 quarters · filed 2024-08-14 | $2.23M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $550.74K 10-Q · filed 2024-05-15 | $1.43M derived: sum of 2 quarters · filed 2024-05-15 | $1.72M derived: sum of 3 quarters · filed 2024-05-15 | $2.37M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $881.33K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $1.17M derived: sum of 2 quarters · filed 2024-04-01 | $1.82M derived: sum of 3 quarters · filed 2024-04-01 | $2.29M 10-K · filed 2024-04-01 |
| 2022-09-30 | $286.52K 10-Q · filed 2023-11-15 | $935.75K derived: sum of 2 quarters · filed 2023-11-15 | $1.41M 10-Q · filed 2023-11-15 | $1.65M derived: sum of 4 quarters · filed 2023-11-15 |
| 2022-06-30 | $649.22K 10-Q · filed 2023-08-14 | $1.12M 10-Q · filed 2023-08-14 | $1.37M derived: sum of 3 quarters · filed 2023-08-14 | $1.68M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $472.34K 10-Q · filed 2023-05-15 | $716.07K derived: sum of 2 quarters · filed 2023-05-15 | $1.04M derived: sum of 3 quarters · filed 2023-05-15 | $1.43M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $243.73K derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-03-31 | $562.89K derived: sum of 2 quarters · filed 2023-03-31 | $956.18K derived: sum of 3 quarters · filed 2023-03-31 | $1.60M 10-K · filed 2023-03-31 |
| 2021-09-30 | $319.16K 10-Q/A · filed 2022-11-15 | $712.45K derived: sum of 2 quarters · filed 2022-11-15 | $1.36M 10-Q/A · filed 2022-11-15 | $3.10M derived: sum of 4 quarters · filed 2022-11-15 |
| 2021-06-30 | $393.29K 10-Q · filed 2022-08-12 | $1.04M 10-Q · filed 2022-08-12 | $2.78M derived: sum of 3 quarters · filed 2022-08-12 | $3.76M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $643.39K 10-Q · filed 2022-05-16 | $2.38M derived: sum of 2 quarters · filed 2022-05-16 | $3.37M derived: sum of 3 quarters · filed 2022-05-16 | $3.91M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $2.72M derived: sum of 2 quarters · filed 2022-03-31 | $3.26M derived: sum of 3 quarters · filed 2022-03-31 | $4.05M 10-K · filed 2022-03-31 |
| 2020-09-30 | $981.90K 10-Q · filed 2021-11-15 | $1.52M derived: sum of 2 quarters · filed 2021-11-15 | $2.31M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $539.23K 10-Q · filed 2021-08-16 | $1.32M 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $784.03K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |